VALBIOTIS SA: Valbiotis announces the success of its €6.9 million rights issue entirely dedicated to supporting the commercial expansion of its offering of dietary supplements

Press Release

Valbiotis announces the success of its €6.9 million rights issue entirely dedicated to supporting the commercial expansion of its offering of dietary supplements

Strong interest from existing shareholders, with a demand of more than €3.0 million

for the rights issue

A renewed commitment of Sébastien Peltier, co-founder and Chairman of the Executive Board,

who subscribed to the operation

La Rochelle, June 26, 2025 (5:40 PM CET) – Valbiotis (FR0013254851 – ALVAL, PEA / PME eligible), a French laboratory specialized in the development and distribution of scientifically tested dietary supplements designed to support health at every stage of life, announces the success of its rights issue. The purpose of this €6.9 million round of financing is to ramp up the Company’s commercial development and enable it to self-finance its growth, while maintaining its focus on its current activities.

Sébastien Peltier, Chairman of the Executive Board and Co-Founder of Valbiotis commented: “I would like to extend my warmest thanks to all the investors who contributed to the success of this operation, both those who secured it upstream through their subscription agreements, and those who joined us during the subscription period. Their confidence in our strategy encourages us to remain committed as Valbiotis enters a particularly exciting phase of its commercial development in France. This round of financing will enable us to step up the pace. We are proud to involve these investors, both private individuals and professionals, in our mission to make Valbiotis a key player in the field of scientifically tested, natural dietary supplements.” 

RESULTS FROM THE OFFERING

At the end of the subscription period, total demand (non-reducible, reducible and unrestricted subscriptions) amounted to 3,447,200 new shares subscribed at a unit price of €0.88, representing around 44.3% of the number of shares to be issued under the capital increase, which involves a total of 7,787,869 new shares. This demand breaks down as follows:

•    2,889,640 shares requested via non-reducible subscriptions, representing 37.1% of the total amount of the issue.
•    240,479 shares requested via reducible subscriptions, representing 3.1% of the total amount of the issue.
•    317,081 shares requested via unrestricted subscriptions, representing 4.1% of the total amount of the issue.

All of these demands (non-reducible, reducible and unrestricted) were served entirely.

Sébastien Peltier, Chairman of the Executive Board and Co-Founder of Valbiotis, subscribed to the operation through unrestricted subscriptions via his personal holding company Djanka Investissement, for an amount of €100,000.

Insofar as these subscription requests represented approximately 44.3% of the amount of the rights issue (i.e., nearly €3.0 million), the 4,340,669 new shares not absorbed by these subscriptions (i.e., 55.7% of the amount of the issue) were distributed and allocated to the shareholders and investors who had undertaken to subscribe under the issue guarantee (together the “Guarantors”). These guarantee commitments could be triggered if the number of new shares subscribed at the end of the subscription period did not reach 100% of the amount of the rights issue. 

As indicated in the press release announcing the launch of the rights issue, the 4,340,669 new shares allocated to the Guarantors, i.e. around €3.8 million corresponding to a service rate of 75.8%, were distributed proportionally among them as follows: 

(*) 6 investors with individual amounts of up to €100K

As a result, the allocated shares were broken down as follows:

REMINDER: USE OF PROCEEDS FROM THE OFFERING

The net proceeds of the issue will amount to around €5.8 million and will be used to support the Company’s commercial expansion. The funds raised will be distributed as follows to support different objectives:

• 60% will be devoted to marketing and communications initiatives aimed at the general public and healthcare professionals, as well as to international commercial development (second half of 2025 and 2026).
• 30% will be used to finance working capital requirements for fiscal years 2025 and 2026, in line with growth in France.
• 10% will be allocated to strengthening the network of Medical Promotion Officers, with planned expansions in three geographical areas.

Given the Company’s cash position at the end of May 2025, and the anticipated ramp-up of business in line with the previously communicated strategic plan, the Company considers that the net proceeds from 100% of the Offering, i.e., €5.8M, will ensure a cash flow horizon well beyond Q3 2026. 

SETTLEMENT & DELIVERY

Settlement and delivery of the New Shares and their admission to trading on Euronext Growth Paris are scheduled for June 30, 2025. The New Shares will carry dividend rights, will be immediately fungible with the Company’s existing shares, and will be traded on the same listing line, under the same ISIN code (FR0013254851 – Ticker Symbol: ALVAL).

Following settlement and delivery, the Company’s share capital will amount to €2,369,823.40 and will be divided into 23,698,234 ordinary shares with a par value of €0.10 each.

IMPACT OF THE OPERATION ON OWNERSHIP STRUCTURE

To the best of the Company’s knowledge, the breakdown of capital and voting rights before and after the rights issue is as follows.

Impact of the Offering on Ownership Structure

Impact of the Offering on Breakdown of Voting Rights